ISIN | LU1540962054 |
---|---|
Valor Number | 35004489 |
Bloomberg Global ID | |
Fund Name | HBM UCITS (Lux) Funds-HBM Global Biotechnology Fund P USD Cap |
Fund Provider |
HBM Partners AG
Zug, Schweiz Phone: +41 43 888 71 71 E-Mail: investorrelations@hbmpartners.com Web: www.hbmpartners.com |
Fund Provider | HBM Partners AG |
Representative in Switzerland |
FundPartner Solutions (Suisse) SA Genève 75 |
Distributor(s) | FundPartner Solutions (Suisse) S.A. |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The investment objective of the Sub-Fund is to achieve long-term capital growth. The goal is to generate a value trend that exceeds the performance of the NASDAQ Biotechnology Index (the “Benchmark”). No guarantee can be given that the investment objective will be achieved. |
Peculiarities |
Current Price * | 432.88 USD | 12.05.2025 |
---|---|---|
Previous Price * | 427.55 USD | 08.05.2025 |
52 Week High * | 522.40 USD | 08.11.2024 |
52 Week Low * | 392.02 USD | 08.04.2025 |
NAV * | 432.88 USD | 12.05.2025 |
Issue Price * | 432.88 USD | 12.05.2025 |
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 19,106,415 | |
Unit/Share Assets *** | 15,311,874 | |
Trading Information SIX |
YTD Performance | -6.26% |
31.12.2024 - 12.05.2025
31.12.2024 12.05.2025 |
---|---|---|
YTD Performance (in CHF) | -12.64% |
31.12.2024 - 12.05.2025
31.12.2024 12.05.2025 |
1 month | +3.09% |
14.04.2025 - 12.05.2025
14.04.2025 12.05.2025 |
3 months | -7.94% |
12.02.2025 - 12.05.2025
12.02.2025 12.05.2025 |
6 months | -14.62% |
12.11.2024 - 12.05.2025
12.11.2024 12.05.2025 |
1 year | -3.36% |
13.05.2024 - 12.05.2025
13.05.2024 12.05.2025 |
2 years | +2.48% |
12.05.2023 - 12.05.2025
12.05.2023 12.05.2025 |
3 years | +23.69% |
18.05.2022 - 12.05.2025
18.05.2022 12.05.2025 |
5 years | -1.51% |
13.05.2020 - 12.05.2025
13.05.2020 12.05.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
argenx SE | 7.92% | |
---|---|---|
Gilead Sciences Inc | 6.07% | |
Vertex Pharmaceuticals Inc | 5.26% | |
Alnylam Pharmaceuticals Inc | 5.12% | |
Amgen Inc | 5.07% | |
Ascendis Pharma AS ADR | 4.22% | |
Axsome Therapeutics Inc | 3.79% | |
Regeneron Pharmaceuticals Inc | 3.44% | |
Merus NV | 3.42% | |
Arcutis Biotherapeutics Inc Ordinary Shares | 3.39% | |
Last data update | 31.03.2025 |
TER | 0.0133% |
---|---|
TER date | 31.01.2018 |
Performance Fee *** | 15.00% |
PTR | |
Max. Management Fee *** | 1.10% |
Ongoing Charges *** | 1.73% |
SRRI ***
|
|
SRRI date *** | 30.04.2025 |